Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism

NCT: NCT07603700 · NOT_YET_RECRUITING

NCT IDNCT07603700
StatusNOT_YET_RECRUITING
Start Date2026-06-01
Completion2029-12-31
SponsorNanjing First Hospital, Nanjing Medical University (OTHER)
First posted
Last updated

Brief Summary

This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑